About NEUROPHET
NEUROPHET is a company based in Seoul (South Korea) founded in 2016 by Donghyeon Kim and Junkil Been. NEUROPHET has raised $24.4 million across 5 funding rounds from investors including Shinhan Bank, SBI Investment Korea and Samjin Pharm. NEUROPHET operates in a competitive market with competitors including Viz.ai, icometrix, RapidAI, Jvion and BrainSightAI, among others.
- Headquarter Seoul, South Korea
- Founders Donghyeon Kim, Junkil Been
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Neurophet, Inc.
-
Annual Revenue
$1.51 M (USD)41.86as on Dec 31, 2024
-
Net Profit
-$10.24 M (USD)-386.93as on Dec 31, 2024
-
EBITDA
-$9.19 M (USD)-26.22as on Dec 31, 2024
-
Total Equity Funding
$24.4 M (USD)
in 5 rounds
-
Latest Funding Round
Not available
-
Investors
Shinhan Bank
& 11 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of NEUROPHET
NEUROPHET is a publicly listed company on the KRX with ticker symbol 380550 in South Korea, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of NEUROPHET
NEUROPHET has successfully raised a total of $24.4M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NEUROPHET
NEUROPHET has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Shinhan Bank, SBI Investment Korea and Samjin Pharm.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sector-agnostic VC firm investing in geographies such as South Korea
|
Locked | Locked | Locked | |
|
Venture capital and private equity are invested in various sectors.
|
Locked | Locked | Locked | |
|
Private equity investments in South Korea are managed.
|
Locked | Locked | Locked |
Investor details for NEUROPHET
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NEUROPHET
Investment portfolio details for NEUROPHET
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NEUROPHET
Detailed financials for NEUROPHET
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neurophet Comparisons
Peer comparison for NEUROPHET
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NEUROPHET
NEUROPHET operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Viz.ai, icometrix, RapidAI, Jvion and BrainSightAI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI and cloud-powered software for stroke care coordination is developed.
|
|
| Locked | Locked | Locked |
AI-based software for brain MRI analysis is provided by icometrix.
|
|
| Locked | Locked | Locked |
Provider of AI-based neuroimaging software for physicians
|
|
| Locked | Locked | Locked |
Deep learning-based illness prediction solutions are provided by Jvion.
|
|
| Locked | Locked | Locked |
Functional brain mapping is enabled by AI-driven connectomics platform.
|
Detailed competitors of NEUROPHET
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neurophet
Complete news archive for NEUROPHET
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NEUROPHET
NEUROPHET was founded in 2016 and raised its 1st funding round 3 years after it was founded.
NEUROPHET is headquartered in Seoul, South Korea.
Donghyeon Kim is the current CEO of NEUROPHET. They have also founded this company.
NEUROPHET is a funded company, having raised a total of $24.4M across 5 funding rounds to date.
Annual revenue of NEUROPHET is $1.51M as on Dec 31, 2024.
NEUROPHET was founded in 2016 in Seoul, South Korea, within the neuro-engineering sector. AI-based simulation software is provided for doctors and researchers focused on electrical brain stimulation. Individual 3D brain models are generated automatically from MRI scans for each patient. Effects of stimulation under various treatment parameters are simulated and analyzed in clinical environments to support medical decision-making.
NEUROPHET's top competitors include Viz.ai, BrainSightAI and RapidAI.
Yes, NEUROPHET is publicly traded on KRX under the ticker symbol 380550.
NEUROPHET has 12 investors. Key investors include Shinhan Bank, SBI Investment Korea, Samjin Pharm, Future Play, and Kolon Investments.
The ticker symbol of NEUROPHET is 380550 on KRX.